ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• ID1 is an oncogenic factor in cancer.
• The role of ID1 in drug sensitivity, particularly in non-small cell lung cancer (NSCLC), remains unclear.
• Understanding ID1's impact on drug sensitivity is crucial for optimizing cancer treatment.

Purpose of the Study:

• To investigate the role of ID1 in modulating drug sensitivity in NSCLC.
• To determine if ID1 influences the response of NSCLC cells to gefitinib.
• To elucidate the molecular mechanisms by which ID1 affects drug sensitivity.

Main Methods:

• ID1 overexpression in NSCLC cell lines with EGFR or KRAS mutations.
• Assessment of NSCLC sensitivity to gefitinib (ZD1839) in vitro.
• Establishment of a murine orthotopic lung carcinoma model with stable ID1 overexpression for in vivo gefitinib treatment.
• Transcriptomic, bioinformatics, and protein kinase array analyses to identify molecular pathways involved.

Main Results:

• ID1 overexpression promoted inflammation-related cell death (necroptosis) rather than apoptosis in gefitinib-treated NSCLC cells.
• ID1 induced necroptosis via activation of the RIP1/RIP3/MLKL pathway.
• ID1 maintained Akt activity, leading to upregulation of FLICE-like inhibitory protein, dissociation of the caspase-8-RIP1 complex, and subsequent necroptosis.

Conclusions:

• ID1 overexpression sensitizes NSCLC to epidermal growth factor receptor tyrosine kinase inhibitors like gefitinib, irrespective of EGFR or KRAS mutational status.
• ID1 induces necroptosis, a key mechanism for gefitinib sensitivity in NSCLC.
• These findings provide a scientific basis for potentially improving gefitinib treatment outcomes in NSCLC patients.